Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.
We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.
08/18/17 4:00 p.m. ET
Minimum 15 minutes delay
- 07/25/17UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
There are currently no events scheduled.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|